LARGE MOLECULE DRUG DELIVERY
The traditional methods of delivering drugs are oral and parenteral.
Large molecules are usually inactivated by oral ingestion, so most
large molecules are delivered by ordinary injection, a method that is
painful and usually requires skilled personnel to administer each dose.
In spite of the current delivery limitations, the current protein drug
market is above $25 billion. Due to advances in biotechnology and
recombinant DNA technology, the potent and expensive protein drug
market is expected to grow significantly.
There are numerous companies working on ways to expand the
means by which large molecule drugs can be delivered transdermally.
Microporation, electroporation, iontophoresis, sonophoresis,
magnetophoresis, and other methods of delivering large molecules
transdermally are under development. However, every one of them to
date has problems, drawbacks, or limitations. Of these, only
iontophoresis has been successfully developed into a marketable
product for local pain relief. However, for significant large molecule
drugs, none have yet achieved market approval.
Using the DrugMAT, a minimally invasive and painless method of
delivering large molecule drugs, the number and variety of indications
for large molecule therapies will expand. By partnering with TheraJect
to use DrugMAT for delivering existing large molecule drugs and
therapies, current product manufacturers and aggressive generic
entrants will gain significant market advantage. As patents for
successful currently injected large molecule drugs approach
expiration, it is clear that improved delivery methods can be the basis
for competitive defense, competitive advantage, and the expansion of
the indications for which large molecule drugs are attractive.